Bloomberg Markets EN

Merck Nears Deal to Buy Terns Pharmaceuticals

Merck & Co. is in advanced talks to buy drugmaker Terns Pharmaceuticals Inc., according to people familiar with the matter.

Mar 25, 2026 &03162525202631; 01:16 UTC feeds.bloomberg.com Trending 3/5

Read original on feeds.bloomberg.com ↗

↗

Positive for markets

Sentiment score: +62/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Merck in advanced acquisition talks with Terns Pharmaceuticals—a fresh, unexpected M&A catalyst that could drive pharma sector rotation. Market context shows S&P 500 slightly down with elevated VIX, suggesting risk-off sentiment may limit immediate upside despite positive deal news.

AI CONFIDENCE

68% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

MRK

MRKStock

Expected to rise

Merck acquisition of Terns is a strategic growth move in pharma; fresh news (19min old) not yet fully priced. Expect modest upside as market digests deal rationale and valuation.

↑

TERNS

TERNSStock

Expected to rise

Target company in M&A deal typically rallies on acquisition announcement; expect significant pop if deal terms are favorable.

↑

Health Care SPDR

XLVETF

Expected to rise

Healthcare sector ETF benefits from pharma M&A activity and Merck strength; modest tailwind from deal sentiment.

⇅

S&P 500

^GSPCIndex

High volatility expected

Broad market headwinds (VIX +3.06%, S&P -0.37%) may cap pharma gains; deal is positive but macro risk-off tone limits sector rotation.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

MRK likely to see modest 1–2% upside on deal announcement; TERNS (if publicly traded) could gap higher. Monitor VIX and S&P reaction—if broad market stabilizes, pharma outperformance accelerates. Avoid chasing if MRK already moved >1% at entry. [MOVE:1.2%]

KEY SIGNALS

Fresh M&A catalyst (19 minutes old, not yet fully absorbed)Advanced talks stage—deal risk remains but momentum is realElevated VIX (26.95) suggests market caution may limit upsideS&P 500 weakness (-0.37%) creates headwind for pharma rally

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 25, 2026 at 01:35 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Bloomberg Markets. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Merck Nears Deal to Buy Terns Pharmaceuticals

RELATED INTELLIGENCE